@article{99aada27fdcb4305bc15f97c0bbcb21c,
title = "Trajectories of IgE sensitization to allergen molecules from childhood to adulthood and respiratory health in the EGEA cohort",
abstract = "BACKGROUND: Longitudinal studies assessing the association of profiles of allergen-specific IgE (sIgE) sensitization to a large range of allergen molecules and respiratory health are rare. We aimed to assess trajectories of molecular sIgE sensitization profiles from childhood to adulthood and their associations with respiratory health.METHODS: IgE reactivity to microarrayed allergen molecules were measured in childhood (EGEA1) and 12 years later in adult life (EGEA2) among 291 EGEA participants (152 with asthma). At each time point, sIgE sensitization profiles were identified by latent class analysis (LCA) by considering IgE-reactivity to the 38 most prevalent respiratory allergens. The LCA-defined profiles were then studied in association with respiratory health.RESULTS: At baseline, the mean (min-max) age of the population was 11 (4.5-16) years. The LCA identified four sIgE sensitization profiles which were very similar at both time points (% at EGEA1 and EGEA2); A: {"}no/few allergen(s){"} (48%, 39%), B: {"}pollen/animal allergens{"} (18%, 21%), C: {"}most prevalent house dust mite allergens{"} (22%, 27%) and D: {"}many allergens{"} (12%, 13%). Overall, 73% of the participants remained in the same profile from childhood to adulthood. The profiles were associated with asthma and rhinitis phenotypes. Participants of profiles C and D had lower FEV1 % and FEF25-75 % as compared to profile A. Similar patterns of associations were observed for participants with asthma. There was no association with change in lung function.CONCLUSION: Using high-resolution sIgE longitudinal data, the LCA identified four molecular sensitization profiles, mainly stable from childhood to adulthood, that were associated with respiratory health.",
keywords = "Adolescent, Allergens, Animals, Antigens, Dermatophagoides, Asthma/diagnosis, Child, Cohort Studies, Humans, Immunoglobulin E, Young Adult",
author = "Val{\'e}rie Siroux and Anne Boudier and Jean Bousquet and Orianne Dumas and Jocelyne Just and {Le Moual}, Nicole and Rachel Nadif and Rapha{\"e}lle Varraso and Rudolf Valenta and Isabelle Pin",
note = "Funding Information: The study was supported in part by ANR‐19‐CE36‐0005‐01 NIRVANA, Inserm Aviesan Itmo sant{\'e} publique, the Scientific committee “AGIR for chronic diseases”, grant F4605 of the Austrian Science Fund (FWF), grant from the Country of Lower Austria and by the Megagrant of the Government of the Russian Federation, grant number 14.W03.31.0024 to Rudolf Valenta and by the European Commission's Seventh Framework Program MeDALL under grant agreement no. 261357. 25‐75 1 Funding Information: I. Pin reports personal fees for presentation from GSK, personal fees from AGIR{\`a}dom and travel support from SANOFI, outside the submitted work. R. Valenta reports grants and personal fees from Viravaxx, Vienna, Austria, grants and personal fees from Worg Pharmaceuticals, Hangzhou, China, grants from HVD Biotech, Vienna, Austria, outside the submitted work. J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. J. Just reports personal fees from Novartis grants from Astra zeneca, personal fees from Thermofischer, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: The study was supported in part by ANR-19-CE36-0005-01 NIRVANA, Inserm Aviesan Itmo sant? publique, the Scientific committee ?AGIR for chronic diseases?, grant F4605 of the Austrian Science Fund (FWF), grant from the Country of Lower Austria and by the Megagrant of the Government of the Russian Federation, grant number 14.W03.31.0024 to Rudolf Valenta and by the European Commission's Seventh Framework Program MeDALL under grant agreement no. 261357. The authors thank all those who participated in the setting of the EGEA study and on the examinations of the individuals. The authors are grateful to the 3 CIC-Inserm of Necker, Grenoble and Marseille who supported the EGEA study and in which participants were examined. They are indebted to all the individuals who participated to the EGEA study without whom the study would not have been possible. The authors acknowledge the EGEA study group: Coordination: V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin (clinical aspects); R Nadif (biology); F Kauffmann (PI 1992-2012). Respiratory epidemiology: Inserm ex-U 700, Paris: M Korobaeff (Egea1), F Neukirch (Egea1); Inserm ex-U 707, Paris: I Annesi-Maesano (Egea1-2); Inserm U 1018, Villejuif: O Dumas, F Kauffmann, N Le Moual, R Nadif, MP Oryszczyn (Egea1-2), R Varraso; Inserm U 1209 Grenoble: J Lepeule, V Siroux. Genetics: Inserm ex-U 393, Paris: J Feingold; Inserm UMR 1124, Paris: E Bouzigon, MH Dizier, F Demenais; CNG, Evry: I Gut (now CNAG, Barcelona, Spain), M Lathrop (now Univ McGill, Montreal, Canada). Clinical centers: Grenoble: I Pin, C Pison; Lyon: D Ecochard (Egea1), F Gormand, Y Pacheco; Marseille: D Charpin (Egea1), D Vervloet (Egea1-2); Montpellier: J Bousquet; Paris Cochin: A Lockhart (Egea1), R Matran (now in Lille); Paris Necker: E Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau: A Grimfeld (Egea1-2), J Just. Data management and quality: Inserm ex-U155, Paris: J Hochez (Egea1); Inserm U 1018, Villejuif: N Le Moual, L Orsi; Inserm ex-U780, Villejuif: C Ravault (Egea1-2); Inserm ex-U794, Evry: N Chateigner (Egea1-2); Inserm UMR 1124, Paris: H Mohamdi; Inserm U1209, Grenoble: A Boudier, J Quentin (Egea1-2). Publisher Copyright: {\textcopyright} 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",
year = "2022",
month = feb,
doi = "10.1111/all.14987",
language = "English",
volume = "77",
pages = "609--618",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",
}